GeneDx Holdings Corp. · NASDAQ:WGS
GeneDx — Sema4 — Q3 2021 Earnings Presentation
12 slides from GeneDx's earnings presentation, 2021
Slide 1: Third Quarter 2021 Earnings Presentation
Third Quarter 2021 Earnings Presentation 1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for
Slide 3: Corporate Snapshot
Corporate Snapshot ~1,150 Employees Guiding to $201- Generating and Database Accessioning 160+ PhD’s1 204mn in total managing 39+ contains 12 > 250,0002 revenue for 2021 petabytes of data million Next Generation per month de-identified Sequencing tests clinical records, annually >500,000 with genomi
Slide 4: Business Highlights
Business Highlights 3Q211 YoY revenue growth of 17%, excluding COVID-19 tests 3Q YoY increase of 36% in diagnostics tests resulted2 Launched Sema4 Elements™, our portfolio of data science-driven products and services to support reproductive and generational health Further strengthened C-suite bench,
Slide 5: Third Quarter GAAP Financial Highlights
Third Quarter GAAP Financial Highlights 3Q 20211 – Financial Highlights 3Q 2021 – Segment Mix USD Millions % Revenue 3Q 2020 3Q 2021 4% 10% Diagnostic Test Total Revenue $38.6 $43.2 COVID GAAP Net Profit ($56.6) $31.42 Gross Profit $2.1 ($15.6) Other 86% Gross Margin 5% (36%) 1 3 months ended 9/30/2
Slide 6: Third Quarter Non-GAAP Financial Highlights
Third Quarter Non-GAAP Financial Highlights 3Q 20211 – Financial Highlights 3Q 2021 – Segment Mix USD Millions % Revenue 3Q 2020 3Q 2021 4% 10% Diagnostic Test Total Adjusted ($23.5) ($65.9) EBITDA2 COVID Adjusted Gross $5.6 ($11.9) Profit3 Other 86% Adjusted Gross 14% (28%) Margin4 1 3 months ended
Slide 7: NorthShore: The first six months
NorthShore: The first six months 7
Slide 8: Accessioned volume growth has accelerated since early September
Accessioned volume growth has accelerated since early September Accessioned volume1 Rolling 4-Week Average 7,000 6,500 6,000 5,500 5,000 4,500 4,000 3,500 9/30/21 4/29/21 2/4/21 10/28/21 6/24/21 3/4/21 7/22/21 5/13/21 5/27/21 8/19/21 9/2/21 4/15/21 10/14/21 7/8/21 9/16/21 2/18/21 1/7/21 1/21/21 6/10
Slide 9: Appendix
Appendix 9
Slide 10: Historical Revenue Mix
Historical Revenue Mix % of Total Revenue1 1Q20 2Q20 3Q20 FY20 1Q21 2Q21 3Q21 Diagnostic Test 99% 93% 84% 79% 73% 87% 86% COVID 0% 6% 14% 18% 25% 8% 10% Other 1% 1% 2% 2% 2% 4% 4% 1 Certain periods do not add to 100% due to rounding 10
Slide 11: Non-GAAP Gross Margin Reconciliation
Non-GAAP Gross Margin Reconciliation USD Millions 11
Slide 12: Non-GAAP EBITDA Reconciliation
Non-GAAP EBITDA Reconciliation USD Millions 12